Lori S. Friedman - Concepedia

Author

Lori S. Friedman

University of California, Berkeley ORCID

Also Known As

Friedman, Lori S., L Friedman, L S Friedman, L. Friedman, L. S. Friedman, L.S. Friedman, Lisa Friedman, Lori Friedman, Lori S Friedman, Lori S. Friedman

297

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

University of California, Berkeley Gene Therapy Laboratory Exelixis (United States)The University of Texas Southwestern Medical Center Charles River Laboratories (United Kingdom)

About

Lori S. Friedman is an author at University of California, Berkeley specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	51	10.8K
2	Natural Sciences	5	5	424
3	Public Health	2	2	367
4	Engineering	1	1	57
5	Health Sciences	1	1	29

Lori S. Friedman

Publications

15.9K

Citations

H-Index

Page 1

	Year	Citations
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Nature Signaling PathwayReceptor Tyrosine KinaseMapk PathwaySystems BiologyMedicine	2010	1.6K
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Cancer Cell Molecular PharmacologySignaling PathwayMedicineReceptor Tyrosine KinasePharmacotherapy	2009	822
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome Annette L. Parks, Kevin R Cook, Marcia Belvin, Nature Genetics BiologyDrosophila Melanogaster GenomeGeneticsGenome StructureSystematic Generation	2004	770
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer Adrian Folkes, Khatereh Ahmadi, W. Alderton, Journal of Medicinal Chemistry Pi3 KinaseChemoprevention StrategyPharmacotherapyPharmaceutical ChemistryTumor Biology	2008	739
Involvement of Brca2 in DNA Repair Ketan J. Patel, Veronica Yu, Hyun‐Sook Lee, Molecular Cell ChromatinGenome InstabilityDna DamageMolecular BiologyMedicine	1998	629
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families Lori S. Friedman, Elizabeth Ostermeyer, Csilla I. Szabo, Nature Genetics Breast OncologySomatic VariantMedicineGeneticsPathology	1994	625
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer Khaled Ali, Dalya R. Soond, Roberto Piñeiro, Nature Cancer ImmunosurveillanceT-regulatory CellImmunologyImmune RegulationCell Death	2014	529
<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Clinical Cancer Research	2009	470
Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53 Michael Ollmann, Lynn Young, Charles J. Di Como, Cell Tumor Suppressor P53Molecular GeneticsDrosophila P53Functional HomologTumor Suppressor	2000	412
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents Michael Degtyarev, Ann De Mazière, Christine Orr, The Journal of Cell Biology	2008	406

Page 1